Evidence map›Paper›PMID 27812180›Full record

ArticlePloS one2016

Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells.

Mohammed I Khan, Anna M Czarnecka, Sławomir Lewicki, Igor Helbrecht, Klaudia Brodaczewska, Irena Koch, Robert Zdanowski, Magdalena Król, Cezary Szczylik

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Toxins · 2023
    Article
  7. Review
  8. Review
  9. Mass spectrometry imaging to explore molecular heterogeneity in cell culture.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  10. Article
  11. Article
  12. Review
  13. Endoglin in the Spotlight to Treat Cancer.International journal of molecular sciences · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Mohammed I KhanMolecular Oncology Laboratory, Department of Oncology, Military Institute of Medicine, Warsaw, Poland.ORCID http://orcid.org/0000-0003-3020-1324
Anna M CzarneckaMolecular Oncology Laboratory, Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Sławomir LewickiDepartment of Regenerative Medicine, Military Institute of Hygiene and Epidemiology, Warsaw, Poland.
Igor HelbrechtMolecular Oncology Laboratory, Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Klaudia BrodaczewskaMolecular Oncology Laboratory, Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Irena KochDepartment of Pathomorphology, Institute of Mother and Child, Warsaw, Poland.
Robert ZdanowskiDepartment of Regenerative Medicine, Military Institute of Hygiene and Epidemiology, Warsaw, Poland.
Magdalena KrólDepartment of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences-WULS, Warsaw, Poland.
Cezary SzczylikMolecular Oncology Laboratory, Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Wojskowy Instytut Medycyny Lotniczej · PLWojskowy Instytut Higieny i Epidemiologii · PLWarsaw University of Life Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent advancement in cancer research has shown that tumors are highly heterogeneous, and multiple phenotypically different cell populations are found in a single tumor. Cancer development and tumor growth are driven by specific types of cells-stem cell-like cancer cells (SCLCCs)-which are also responsible for metastatic spread and drug resistance. This research was designed to verify the presence of SCLCCs in renal cell cancer cell lines. Subsequently, we aimed to characterize phenotype and cell biology of CD105+ cells, defined previously as renal cell carcinoma tumor-initiating cells. The main goal of the project was to describe the gene-expression profile of stem cell-like cancer cells of primary tumor and metastatic origin. MATERIALS AND

methodsReal-time PCR analysis of stemness genes (Oct-4, Nanog and Ncam) and soft agar colony formation assay were conducted to check the stemness properties of renal cell carcinoma (RCC) cell lines. FACS analysis of CD105+ and CD133+ cells was performed on RCC cells. Isolated CD105+ cells were verified for expression of mesenchymal markers-CD24, CD146, CD90, CD73, CD44, CD11b, CD19, CD34, CD45, HLA-DR and alkaline phosphatase. Hanging drop assay was used to investigate CD105+ cell-cell cohesion. Analysis of free-floating 3D spheres formed by isolated CD105+ was verified, as spheres have been hypothesized to contain undifferentiated multipotent progenitor cells. Finally, CD105+ cells were sorted from primary (Caki-2) and metastatic (ACHN) renal cell cancer cell lines. Gene-expression profiling of sorted CD105+ cells was performed with Agilent's human GE 4x44K v2 microarrays. Differentially expressed genes were further categorized into canonical pathways. Network analysis and downstream analysis were performed with Ingenuity Pathway Analysis.

resultsMetastatic RCC cell lines (ACHN and Caki-1) demonstrated higher colony-forming ability in comparison to primary RCC cell lines. Metastatic RCC cell lines harbor numerous CD105+ cell subpopulations and have higher expression of stemness genes (Oct-4 and Nanog). CD105+ cells adopt 3D grape-like floating structures under handing drop conditions. Sorted CD105+ cells are positive for human mesenchymal stem cell (MSC) markers CD90, CD73, CD44, CD146, and alkaline phosphatase activity, but not for CD24 and hematopoietic lineage markers CD34, CD11b, CD19, CD45, and HLA-DR. 1411 genes are commonly differentially expressed in CD105+ cells (both from primary [Caki-2] and metastatic RCC [ACHN] cells) in comparison to a healthy kidney epithelial cell line (ASE-5063). TGF-β, Wnt/β-catenine, epithelial-mesenchymal transition (EMT), Rap1 signaling, PI3K-Akt signaling, and Hippo signaling pathway are deregulated in CD105+ cells. TGFB1, ERBB2, and TNF are the most significant transcriptional regulators activated in these cells.

conclusionsAll together, RCC-CD105+ cells present stemlike properties. These stem cell-like cancer cells may represent a novel target for therapy. A unique gene-expression profile of CD105+ cells could be used as initial data for subsequent functional studies and drug design.

Indexed as

Gene Expression ProfilingAC133 AntigenBiomarkers, TumorCarcinoma, Renal CellEndoglinEpithelial-Mesenchymal TransitionHumansKidney NeoplasmsNanog Homeobox ProteinNeoplastic Stem CellsOctamer Transcription Factor-3Oligonucleotide Array Sequence AnalysisSpheroids, CellularTumor Cells, CulturedAC133 AntigenBiomarkers, TumorEndoglinENG protein, humanNanog Homeobox ProteinNANOG protein, humanOctamer Transcription Factor-3POU5F1 protein, humanPROM1 protein, human

Identifiers

PMID27812180
PMCPMC5094751
OpenAlexW2546540003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.